Recent developments in bacterial conjugate vaccines

Journal of Medical Microbiology

Volumn 47, Issue 7, 1998, Pages 563-567

  Goldblatt, D ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MENINGITIS VACCINE; OUTER MEMBRANE PROTEIN; POLIOMYELITIS VACCINE; STREPTOCOCCUS VACCINE;

ANTIBODY RESPONSE; B LYMPHOCYTE; BACTERIAL MENINGITIS; CHILDHOOD DISEASE; DIPHTHERIA; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; NEISSERIA MENINGITIDIS; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; TETANUS; VACCINE PRODUCTION;

EID: 0031809818     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-47-7-563     Document Type: Review

References (41)

1. Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med 1929; 50: 533-550.
2. Baker PJ. T cell regulation of the antibody response to bacterial polysaccharide antigens: an examination of some general characteristics and their implications. J Infect Dis 1942; 165 Suppl 1: S44-48.
3. Peltola H, Käyhty H, Sivonen A, Mäkelä H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60: 730-737.
4. Käyhty H, Karanko V, Peltola H, Mäkelä PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984; 74: 857-865.
5. Zahradnik JM, Gordon LK. Augmented antibody [Ab] responses in infants administered a new Haemophilus influenzae type b capsular polysaccharide [PRP] diphtheria toxoid conjugate vaccine [PRP-D]. Pediatr Res 1984; 18: 289A.
6. Ward J, Berkowitz C, Pescetti J, Burkart K, Samuelson J, Gordon L. Enhanced immunogenicity in young infants of a new Haemophilus influenzae type b (H1B) capsular polysaccharide (PRP)-diphtheria toxoid (D) conjugate vaccine. Pediatr Res 1984; 18: 287A.
7. Granoff DM, Anderson EL, Osterholm MT et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992; 121: 187-194.
8. Käyhty H, Eskola J, Peltola H, Saarinen L, Mäkelä PH. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharides or conjugate vaccine after primary immunization with conjugate vaccines. J Infect Dis 1992; 165 Suppl 1: S165-166.
9. Zepp F, Schmitt HJ, Kaufhold A et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur J Pediatr 1997; 156: 18-24.
10. Goldblatt D, Pinto Vas R, Miller K. Antibody avidity as a surrogate marker of successful priming following Haemophilus influenzae type b conjugate vaccine. J Infect Dis 1997 (in press).
11. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340: 592-594.
12. Ambrosino DM, Sood S, Lee MC et al. IgG1, IgG2 and IgM responses to two Haemophilus influenzae type b conjugate vaccines in infants. Pediatr Infect Dis J 1992; 11: 855-859.
13. Goldblatt D, Fairley CK, Cartwright K, Miller E. Interchangeability of conjugated Haemophilus influenzae type b vaccines during the primary immunisation of infants. BMJ 1996; 312: 817-818.
14. Lieberman JM, Greenberg DP, Wong VK et al. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines. J Pediatr 1995; 126: 198-205.
15. Barington T, Gyhrs A, Kristensen K, Heilmann C. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun 1994; 62: 9-14.
16. Santosham M, Wolff M, Reid R et al. The efficacy in Navajo infants of conjugate vaccine consisting of Haemophilus influenza type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324: 1767-1772.
17. Booy R, Heath PT, Slack MPE, Begg N, Moxon ER. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 1997; 349: 1197-1202.
18. Mulholland K, Hilton S, Adegbola R et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349: 1191-1197.
19. Eskola J, Olander R, Hovi T, Litmanen L, Peltola S, Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996; 348: 1688-1692.
20. Mills EL, Russell M, Cunning L et al. A fully liquid acellular pertussis vaccine combined with IPV and Hib vaccines (DTaP-IPV-PRP-T) is safe and immunogenic without significant interaction. ICAAC 1997; G-95 [Abstract].
21. Twumasi PA, Kumah S, Leach A et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995; 171: 632-638.
22. Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996; 174: 1360-1363.
23. Fusco PC, Michon F, Tai JY, Blake MS. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J Infect Dis 1997; 175: 364-372.
24. George RC, Ball LC, Cooper PG. Antibiotic-resistant pneumococci in the United Kingdom. Commun Dis Rep CDR Rev 1992; 2: R37-43.
25. Simberkoff MS. Drug-resistant pneumococcal infections in the United States. A problem for clinicians, laboratories, and public health. JAMA 1994; 271: 1875-1876.
26. Privitera G. Penicillin resistance among Streptococcus pneumoniae in Europe. Diagn Microbiol Infect Dis 1994; 19: 157-161.
27. Simberkoff MS, Cross AP, Al-Ibrahim M et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration cooperative study. N Engl J Med 1986; 315: 1318-1327.
28. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-1460.
29. Scott JAG, Hall AJ, Dagan R et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin Infect Dis 1996; 22: 973-981.
30. Sniadack DH, Schwartz B, Lipman H et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children - implications for vaccine strategies. Pediatr Infect Dis J 1995; 14: 503-510.
31. Greenwood BM, Hassan-King M, Macfarlane JT et al. Pneumococcal serotypes in West Africa. Lancet 1980; 1: 360.
32. Mastro TD, Ghafoor A, Nomani NK et al. Antimicrobial resistance of pneumococci in children with acute lower respiratory tract infection in Pakistan. Lancet 1991; 337: 156-159.
33. Leach A, Ceesay SJ, Banya WAS, Greenwood BM. Pilot trial of a pentavalent pneumococcal polysaccharide, protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J 1996; 15: 333-339.
34. Åhman H, Käyhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996; 15: 134-139.
35. Pichichero ME, Shelly MA, Treanor JJ. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Pediatr Infect Dis J 1997; 16: 72-74.
36. Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996; 128: 649-653.
37. O'Brien KL, Steinhoff MC, Edwards K, Keyserling H, Thoms ML, Madore D. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr Infect Dis J 1996; 15: 425-430.
38. King JC, Vink PE, Farley JJ et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15: 192-196.
39. Dagan R, Melamed R, Muallem M et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174: 1271-1278.
40. Obaro SK, Adegbola RA, Banya WAS, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996; 348: 271-272.
41. Mbelle N, Wasas A, Huebner R, Kimura A, Chang I, Klugman K. Immunogenicity and impact on carriage of 9-valent pneumococcal conjugate vaccine given to infants in Soweto, South Africa. ICAAC 1997; LB21 [Abstract].